Press Release/ Public Statement 03/26/2021 The FDA problems an emergency usage authorization (EUA) to a business for the SARS-Co, V-2 NGS Assay and supplies a consumer upgrade on common concerns about COVID-19 vaccines. COVID-19 Update 3/24/2021 Responses from the FDA to typical concerns about COVID-19 vaccines. Consumer Info 03/17/2021 FDA leadership will take part in your home Subcommittee on Oversight and Examinations of the Committee on Energy and Commerce hearing entitled, "Blazing a trail Forward: Biden Administration Actions to Increase COVID-19 Vaccinations." View livestream and composed testament Event 03/05/2021 FDA's Workplace of Minority Health and Health Equity discusses the company's efforts to stop fraudulent items from reaching our markets, specifically those claiming to avoid, treat, or cure COVID-19.
Post 03/02/2021 The FDA concerns Voices on safeguarding customers against COVID-19 vaccine rip-offs and concerns a caution letter to a business selling unapproved items with fraudulent COVID-19 claims. News Release/ Public Statement 02/27/2021 Today, the U.S. Food and Drug Administration released an emergency use permission (EUA) for the third vaccine for the avoidance of coronavirus illness 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-Co, V-2). Press Release/ Public Statement 02/26/2021 Following today's favorable advisory committee meeting result regarding the Janssen Biotech Inc. COVID-19 Vaccine, the FDA has actually informed the sponsor that it will rapidly pursue completion and issuance of an emergency situation usage authorization.
COVID-19 Update 02/26/2021 The Vaccines and Related Biological Products Advisory Committee will meet in open session to go over Emergency Usage Permission (EUA) of the Janssen Biotech Inc. COVID-19 Vaccine for active immunization to prevent COVID-19 brought on by SARS-Co, V-2 in people 18 years and older. View livestream Event 02/25/2021 Today, the FDA revealed that it is allowing undiluted frozen vials of the Pfizer-Bio, NTech COVID-19 Vaccine to be carried and saved at standard temperatures typically discovered in pharmaceutical freezers for a period of up to two weeks. News Release/ Public Statement 02/23/2021 FDA released assistances for medical product designers to attend to the introduction and potential future development of variations of SARS-Co, V-2.